new info Covid 新資料

1. 打疫苗後重新感染只有0.008%,而且這當中只有7%住院The so called “ breakthrough” is 5800 of reinfected cases out of 66 million fully vaccinated (got 2 doses of vaccines) Americans  -(0.008percent of happening ). And only 1 death. (1 out of 66 million) 

Cdc official data 

https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html

A separate Wall Street Journal report points outthat the 5,800 CDC-reported cases represent just 0.008 percent of the group of 66 million fully vaccinated Americans. Data on this issue, often referred to as “breakthrough cases,” is slightly delayed. At the time of this writing, the CDC was reporting that roughly 77 million people had been fully vaccinated in the U.S.

https://www.yahoo.com/entertainment/cdc-reports-extremely-small-number-171705438.html?soc_src=social-sh&soc_trk=fb&tsrc=fb

2. Thrombosis thrombocytopenia syndrome (tts ) , meaning cvst combined with low platelet has not occurred in almost 200million of mRNA vaccines given in the us. It is either cvst or low platelet but not both.

Cvst may develop in 4-21 days after vaccination 

牛津大学疫苗病例来看，血栓症状出现在接种疫苗后的5-24天，绝大部分在接种1-2周后。通过分析医疗档案，研究人员发现，确诊新冠后的两周时间里，病人发生脑静脉血栓的风险是每百万人39例，而接种mRNA疫苗后的同一时间段里是每百万人4.1例。后者与之前欧洲推测的阿斯利康/牛津大学疫苗每10-25万一例CVST非常接近。这也是为什么很多人的关注点成了所有疫苗都有脑血栓风险。但要注意的是这项研究观察的是所有脑血栓，而被认为是阿斯利康/牛津大学疫苗罕见不良反应的血栓是伴随血小板减少，并非一个概念。

而且由于只有不到50万mRNA疫苗接种者的档案对应两例脑血栓，这项研究并不适合估计mRNA疫苗的血栓风险，真正的关键结果是在50万新冠患者里有20例脑血栓。也就是说哪怕只看脑血栓，新冠带来的风险也远高于疫苗罕见不良反应的风险。

况且新冠带来的健康危险远不止脑血栓。所以在考虑疫苗血栓风险的时候，我们不能只盯着每一例CVST是否与疫苗有关，要考虑

整体的风险收益

，不能忘了疫苗防护新冠带来的收益。

Cvst 症狀：

Cvst: usually occur within 14 days 

It’s expected to have headache for 1-2 days 

But, Increasingly severe headache after 2 days 

Blurry vision

Without feeling nausea, you suddenly vomit 

For blood clots in the intestinal area 

1. Stomach pains 
2. Within 4-16 days 

Low platelet ( less than 10k) will have bleeding situation 

1. toothbrushing - your gums might bleed 
2. Unexplained bruises 

3. AZ vaccine related to Heparin-induced thrombocytopenia (HIT): heparin combines with platelet factor 4 to form a complex. Triggered by heparin, the immune system release anti platelet factor 4 to attack the complex, thus leading to blood clots. 

4. 4/14 CDC J&J vaccine report with graphs 

https://www.cdc.gov/vaccines/acip/meetings/slides-2021-04.html

5. Out of 88 million vaccination of Moderna, only 3 CVST but without low platelet so it is not TTE. None cvst in Pfizer so far 

6. Vaccination by age group 

(Cdc report )

7. 嚴重過敏反應比例 anaphylaxis 

8. herd immunity 群體免疫 可能要至少70%, 特別是因為有更多變種病毒(per Dr Yebin)

4. 4/20 percentage of people who have got the vaccine by age group and fatality rate 4/20 美國各年齡層接受疫苗比例，各年齡層死亡率，死亡率隨著疫苗接種比例上升而下降

--------

7. 4/21  FDA:  J&J, Pfizer,, Moderan CVST, 

a. . J&J 疫苗血栓:根據美國FDA、CDC提供的最新數據，總計有約720萬人接種了強生疫苗，共有8例伴隨血小板減少的嚴重血栓（世界衛生組織給出的定名，簡稱TTS），7例是疫苗上市後發現（強生暫停時是6起確認，1起在研究中，如今這一起也被確認），1例是臨床試驗中出現，現被回溯確認。發生位置以罕見的腦部居多（CVST）——強生8例中7例有CVST。

b. Pfizer 輝瑞在美國接種超過9000萬針，沒有發現CVST；

Moderna接種8000萬針，3例CVST，但這3例沒有伴隨血小板減少，

AZ: 阿斯利康/牛津大學疫苗（該疫苗目前記錄有287例）Ａ

4/1 歐盟:  截至4月13日的數據匯總，伴隨血小板減少的嚴重血栓（包括CVST+blood clots），輝瑞25例，Moderna 5例。(應該是美國＋全世界）

以伴隨血小板下降的罕見血栓為例——也就是最近刷屏的CVST討論，阿斯利康/牛津大學疫苗的發生率最高預計十萬分之一，而強生目前是百萬分之一（集中於接種後兩周）。這些都高於自然背景下的發生率（CVST本身發生率在每百萬人每年3-15例，對應兩周每百萬人0.6例，歐洲新聞發佈會上提到伴隨血小板下降的或為這一總數的7%）——這是我們認為這一不良反應與疫苗很可能有關的重要依據。

歐洲強生疫苗風險評估新聞發佈會：https://www.youtube.com/watch?v=C9mY0_yz2io

CDC專家會議資料：https://www.cdc.gov/vaccines/acip/meetings/slides-2021-04.html

牛津大學論文預印本：https://osf.io/a9jdq/ 

8. 這項技術似乎是新技術，但建立在多年研究技術的基礎上。 某些癌症和癌症的mRNA疫苗狂犬病已經在人類的臨床試驗中使用,有多年的成果，並沒有明顯的安全問題

https://www.immunology.org/sites/default/files/BSIresource_A_guide_to_vaccinations_for_COVID19.pdf 

9. 4/23 johnson and johnson vaccine restarted:

2.上週施打680萬劑後有6例CVST併血小板低下，目前累積到21日之前798萬劑後有15例TTS（血栓併血小板低下症候群）。且還有一些案例正在確認中。其中有3例死亡，7例住院中（4例在ICU），5例已經康復出院。

3.這15例TTS都是女性，年齡中位數是37歲，有13例是50歲以下。在50歲以下女性的發生率是百萬分之7，30~39歲佔了8例最多，百萬分之11.8。50歲以上則是百萬分之0.9。

As of April 21, the number of cases rose to 15, with three deaths. Seven patients remain hospitalized, including four in the ICU, while five were discharged home.

Thirteen of these cases were in women ages 18-49, with two in women older than 50. Based on these data, Tom Shimabukuro, MD, of the CDC, estimated that the rate of TTS was 7.0 per million doses in younger women, and 0.9 per million in older women. Seven cases of 15 were among women ages 30-39.

While all cases were in women,Median patient age was 37, with a median time to onset of 8 days following vaccination. While 12 cases were CVST, three were other forms of thrombosis. Seven patients had obesity, while two patients apiece reported oral contraceptive use, hypothyroidism, or hypertension. No patients had established coagulation disorders.
各種疫苗副作用發生機率比例Every type of Side effect in covid vaccine@@ did fda skip phases or take short cut to pass the covid vaccine 




Can covid vaccine change our dna ?